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with increased risk of mortality and myocardial infarction after cor-
onary intervention. Beneﬁcial effect of clopidogrel may be attenuated
by drug interaction with PPI.
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BACKGROUND Recently, ACEF (age, creatinine, ejection fraction)
score showed prognostic value predicting major adverse cardiac
events (MACEs) in patients undergoing percutaneous coronary inter-
vention (PCI) after acute myocardial infarction (AMI). However, it has
not been fully validated yet in large population. We aimed to assess
whether ACEF score would improve the ability of the GRACE score to
predict MACEs of patients undergoing PCI after AMI.
METHODS Between November 2005 and July 2014, 11,549 patients
(8,442 men; 6313 year-old) underwent PCI after AMI were included
from Korean AMI registry. The ACEF score was calculated as follows:
age/left ventricular ejection fraction þ 1 if serum creatinine >2 mg/dL.
The 1-year MACEs were stratiﬁed according to ACEF score tertiles;
ACEFLOW 1.07 (n¼3,828), 1.07 < ACEFMID  1.44 (n¼3,848), and
ACEFHIGH> 1.44 (n¼3,873). The 1-year MACEs were deﬁned as death,
non-fatal MI, and revascularizations.
RESULTS During the follow-up, rate of MACE was signiﬁcantly higher
in the highest tertile group compared with patients in the lower 2
tertiles (8.5% versus 10.5% versus 24.0%; log-rank p<0.001). In Cox-
proportional hazards model, ACEF score (hazards ratio [HR] 1.60,
p<0.001) in addition to Killip class >1 (HR 1.39, p<0.001), anterior MI
(HR 1.13, p¼0.035), diabetes mellitus (HR 1.27, p<0.001), multivessel
disease (HR 1.51, p<0.001), pre TIMI ﬂow 0 or 1 (HR 1.19, p¼0.07), and
GRACE score (HR 1.01, p<0.001) was an independent predictor of 1-
year MACEs. The respective C-statistics from ACEF score was signiﬁ-
cantly higher compared with those of GRACE score in terms of 1-year
MACEs (0.672 versus 0.651, p¼0.0005) and mortality (0.807 versus
0.777, p¼0.0001). The ACEF score signiﬁcantly improved net reclas-
siﬁcation of patients compared to GRACE score in terms of 1-year
MACEs (0.153, p<0.001) and mortality (0.038, p<0.0001), and also
signiﬁcantly improved integrated discrimination of patients
compared to GRACE score in terms of 1-year MACEs (0.085, p¼0.005)
and mortality (0.028, p<0.001).
CONCLUSIONS The ACEF score improves the discrimination accuracy
of conventional risk model to predict MACEs of patients underwent
PCI after AMI.
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BACKGROUND STEMI patients are at increased risk for recurrent
ischemic events, and guidelines recommend potent P2Y12 inhibitors
for the duration of at least one year after primary PCI. The frequency
and clinical impact of premature prasugrel cessation or a change to
clopidogrel or ticagrelor following primary PCI remains unknown.
METHODS Between September 2009 and June 2012, 1382 patients
with STEMI undergoing primary PCI using newer generation DES and
discharged on dual antiplatelet therapy with prasugrel and aspirin
were enrolled in the framework of the Comfortable trial, SPUM ACS
registry and Bern PCI registry. Prasugrel was prescribed for one year.
Clinical follow-up information was obtained at discharge, 30 days and
one year. Prespeciﬁed categories for prasugrel cessation included
disruption (non-compliance, bleeding, side effects), physician rec-
ommended discontinuation or a change to clopidogrel. All adverse
events and information on prasugrel cessation was collected and
independently adjudicated according to the 3 categories. Using cox
regression models with time-dependent variables, we assessed the
effect of prasugrel cessation on cardiovascular outcomes. The primary
outcome measure was deﬁned as cardiac death, reinfarction, and
stroke. Secondary endpoints included death, cardiac death, reinfarc-
tion and deﬁnite stent thrombosis.
RESULTS A total of 1,382 STEMI patients were included: 1,196 (86.5%)
patients completed DAPT on prasugrel throughout one year; Prasugrel
was disrupted in 48 (3.5%) patients, discontinued in 42 (3%) patients
and switched to another P2Y12 inhibitor in 95 (6.9%) patients. The
adjusted hazard ratio (HR) for MACE after prasugrel disruption tended
to be increased (2.34 (95% CI 0.85-6.38); p¼0.098), while no differ-
ence was observed after premature discontinuation (HR¼ 1.43 (95 CI
0.34-5.91); p¼0.63) or change in type of P2Y12 therapy (HR¼1.20 (95%
CI 0.48-3.01); p¼0.69); in each case compared to the period the pa-
tients were on DAPT with prasugrel. Disruption was associated with
an increased risk of death (6.09, 95% CI 1.72-21.59, p¼0.005), cardiac
mortality (HR¼4.63, 95% CI 1.00-21.54; p¼0.05) and stent thrombosis
(HR¼4.22, 95% CI 1.27-14.05, p¼0.019), while there was a trend to-
wards an increased risk of MI (HR¼2.78, 95% CI 0.86-8.94, p¼0.087).
CONCLUSIONS A high proportion STEMI patients remained on DAPT
with prasugrel throughout one year after primary PCI in routine
clinical practice. Prasugrel disruption is infrequent but associated
with an increased risk for ischemic cardiovascular events compared to
physician guided discontinuation or change to clopidogrel.
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BACKGROUND Several conditions may mimic a true ST Elevation
Myocardial Infarction (STEMI) and lead to false activation of the
Cardiac Catheterization Laboratory (CCL). We investigated the rea-
sons for false STEMI activations at our institution.
METHODS We reviewed the medical records of all patients presenting
to our institution for percutaneous coronary intervention for possible
STEMI from July 2012 to November 2014. A false STEMI activation was
B102 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5deﬁned as a lack of clinical and electrocardiographic evidence of
ongoing myocardial infarction. Patients who underwent cardiac
catheterization without an obvious culprit lesion corresponding to the
ECG changes were also included as false STEMI. The diagnoses were
obtained based upon the clinical presentation and ECG ﬁndings as
well as transthoracic echocardiogram and coronary angiography
ﬁndings in some cases.
RESULTS Of the 431 STEMI activations, (356/431) 82.6% were males
and 17.4% (75/431) were females. The overall false STEMI activation
rate was 35.3% (152/431). There were 23% (35/152) females and 77 %
(117/152) males who had false STEMI activations (p 0.023). The most
frequent cause for false STEMI activation was abnormal ECG ﬁndings-
19% (29/152), of which presumed new Left Bundle Branch Block
accounted for 48% of these. 12.5% had non cardiac chest pain (19/152)
and 11.8% (18/152) had Non STEMI (NSTEMI). Coronary artery vaso-
spasm occurred in 7.9% (12/152) of cases. Pericarditis was diagnosed in
(6.6%) 10/152 and severe hypertension in 5.9% (9/152). There were
5.2% cases (8/152) with a diagnosis of acute or decompensated
Congestive Heart Failure (CHF), unstable angina and syncope each.
4.6% (7/152) had cardiac arrest. Pericardial effusion was found in 3.3%
(5/152) patients. Three patients (2%) were diagnosed each with Bru-
gada and Takotsubo. Two patients (1.3%) had pulmonary embolism
(PE), aortic dissection and Implantable Cardioverter Deﬁbrillator (ICD)
shocks each. Less common causes were endocarditis, Intracranial
Hemorrhage (ICH), Subdural Hematoma, severe Aortic Regurgitation
(AR), severe anemia, ventricular aneurysm and sepsis where 1 case of
each was observed.
CONCLUSIONS The commonest reason for False STEMI activation
was the ﬁnding of an abnormal ECG. Presumed new LBBB accounted
for 48% of the ECG abnormalities.
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BACKGROUND Anterior ST-segment elevation infarction (A-STEMI) is
associated with larger infarct size and greater reduction in left ven-
tricular ejection fraction (LVEF) compared with non-anterior STEMI
(NA-STEMI). Whether or not ECG-deﬁned STEMI location predicts
long-term mortality after primary percutaneous coronary intervention
(PPCI) is unclear. We sought to investigate: (i) the clinical and quan-
titative coronary angiography (QCA) characteristics of patients with
ECG-deﬁned A- and NA-STEMI, and (ii) the unadjusted andindependent long-term prognostic impact of ECG-deﬁned STEMI
location in patients undergoing PPCI.
METHODS Participants from the HORIZONS-AMI trial were catego-
rized according to A-STEMI vs. NA-STEMI ECG-deﬁned STEMI loca-
tion. By ECG core laboratory analysis, A-STEMI was deﬁned as an ST-
elevation in the anterior (V2-4) or anteroseptal (V1-3) ECG leads. Pri-
mary endpoint of interest was all-cause mortality at 3 years. Adjusted
associations with 3-year mortality were estimated by Cox proportional
hazards modeling.
RESULTS Among 2,578 patients undergoing PPCI with core laboratory
determined STEMI location, 765 (29.7%) and 1813 (70.3%) hadA-STEMI and
NA-STEMI respectively. Patients with A-STEMI were older and had lower
baseline LVEF. Left anterior descending (LAD) artery was the culprit artery
in 90.9% of A-STEMIs, while the right coronary and left circumﬂex (LCX)
were the culprit arteries in 61.7% and 17.4%of NA-STEMIs, respectively. By
QCA, lesion length was longer, and thrombus, calciﬁcation, and type B2/C
lesions were more prevalent in NA-STEMI. At 3 years, patients with A-
STEMI had higher unadjusted rates of 3-year all-cause mortality (7.6% vs.
4.8%; p¼ 0.004). This association persisted aftermultivariable adjustment
for baseline clinical confounders (hazard ratio [HR]: 1.42; 95% conﬁdence
interval [CI]: 1.19 – 1.69; p<0.0001). However, after includingQCAvariables
in the multivariable model, ECG-deﬁned A-STEMI had no effect on 3-year
mortality (HR: 1.03; 95% CI: 0.77 – 1.37; p¼0.84); conversely, QCA variables
such as LAD as a culprit artery, presence of LCX plaques with > 50% di-
ameters stenosis (DS), presence of left main plaques with > 50% DS, and
total lesion length did.
CONCLUSIONS ECG-deﬁned A-STEMI was associated with greater
long-term mortality in patients undergoing primary PCI from HORI-
ZONS-AMI. QCA variables, however, including infarct artery location,
had better long-term prognostic value than ECG-deﬁned STEMI
location.
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BACKGROUND It is known that elevated inﬂammatory biomarkers
were associated with clinical outcomes of patients with ST-segment
elevated myocardial infarction (STEMI). This study investigated the
usefulness of a novel inﬂammation-based prognostic system, named
the combination of platelet count and neutrophil-lymphocyte ratio
(COP-NLR) for predicting prognosis of patients with STEMI.
METHODS We analysis 305 consecutive patients with STEMI treated
with primary PCI. The COP-NLR was calculated as follows: patients
with both an elevated platelet count (> 300  109/l) and neutrophil
lymphocyte ratio (> 3) were allocated a score of 2 and patients
showing one or neither were allocated a score of 1 or 0, respectively.
RESULTS The patients with COP-NLR score 0, 1, and 2 was 102, 149,
and 23 patients, respectively. The peak CK-MB (181.4 ng/ml, 219.7 ng/
ml, and 265.1 ng/ml, respectively, ANOVA P ¼ 0.070) and Troponin T
numerically increased according to COP-NLR score (0.63 ng/ml, 0.78
ng/ml, and 1.57 ng/ml, respectively, ANOVA P ¼ 0.059). During the
PCI, no-reﬂow tended to be observed more frequently in patients with
score 2 (2.8%, 4.7%, and 10.3%, respectively, P ¼ 0.117).The in-hospital
mortality was highest in COP-NLR score 2 (0%, 4.7%, and 13.8%,
respectively, P ¼ 0.002). The Kaplan-Meier curve showed that higher
COP-NLR score signiﬁcantly associated with major cardiovascular
adverse events in 12-month follow-up.
Short-term and long-term clinical outcomes according to COP-NLR scoreCOP-NLR score 0
N [ 106COP-NLR score 1
N [ 161COP-NLR score 2
N[25 P-valueIn-hospital death 0, 0% 8, 4.7% 4, 13.8% 0.001All cause death 0, 0% 9, 5.3% 4, 13.8% 0.003Non-fatal MI 3, 2.8% 3, 1.8% 1, 3.4% 0.771TLR 5, 4.7% 3, 1.8% 0, 5% 0.231MACE 7, 6.6% 16, 9.4% 6, 20.7% 0.072
